Samsung Bioepis, the joint venture between Samsung BioLogics and Biogen, has announced that its filing for a US biosimilar rival to Genentech’s Avastin (bevacizumab) has been accepted for review by the US Food and Drug Administration.
FDA Reviews Samsung Bioepis’ Bevacizumab
Avastin Rival Will Be Sold Through Merck, Sharp & Dohme
Samsung Bioepis has announced that its SB8 biosimilar bevacizumab candidate, a proposed US rival to Avastin, has been accepted for review by the FDA.
More from Biosimilars
In the aftermath of last week’s J.P. Morgan Healthcare Conference in San Francisco, Generics Bulletin’s editorial team brings you additional coverage of items of interest for the global generics and biosimilars industry.
Henlius casts a wider net for its biosimilars presence by locking in a fresh deal with the already-established partner Abbott. Also, the Chinese biosimilars developer has joined the Biosimilars Forum, securing its footing in the US.
Recently-appointed president of Medicines for Europe Stephan Eder speaks to Generics Bulletin about the off-patent association’s priorities to secure a sustainable operating environment for the generics, biosimilars and value-added medicines sector in Europe.
While Amneal cannot wait to jump into unexplored biologics space, it wants to channel its GLP-1 power into the Metsera partnership and service big pharma, and less so on its own generics.
More from Products
Hungary’s Gedeon Richter and its Japanese partner Mochida have together unveiled plans to file their proposed Actemra/RoActemra biosimilar with major regulators, after biosimilar competition to the IL-6 receptor inhibitor materialized in the US last year.
As Bob Bradway addressed the J.P. Morgan Healthcare Conference in San Francisco, the Amgen chief executive discussed the firm’s biosimilars business – including an ocrelizumab rival to Ocrevus that has just been added to its pipeline. Meanwhile, the CEO also outlined his expectations for imminent biosimilar competition to Amgen’s Prolia and Xgeva denosumab brands.